DNER and cancer: It remains to be determined whether monotherapy with BET bromodomain inhibitors will show significant efficacy within an acceptable therapeutic window or whether combinations with other anti-cancer drugs will be required to increase the therapeutic impact of BET inhibitors [31, 32].